IS2325B - Örgerðar samsetningar epleróns - Google Patents

Örgerðar samsetningar epleróns

Info

Publication number
IS2325B
IS2325B IS5953A IS5953A IS2325B IS 2325 B IS2325 B IS 2325B IS 5953 A IS5953 A IS 5953A IS 5953 A IS5953 A IS 5953A IS 2325 B IS2325 B IS 2325B
Authority
IS
Iceland
Prior art keywords
microplated
eplerone
formulations
microplated formulations
Prior art date
Application number
IS5953A
Other languages
English (en)
Other versions
IS5953A (is
Inventor
Dwain S Tolbert
Rajeev D Gokhale
Shilpa S Thosar
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22339668&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2325(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of IS5953A publication Critical patent/IS5953A/is
Publication of IS2325B publication Critical patent/IS2325B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IS5953A 1998-12-09 2001-05-25 Örgerðar samsetningar epleróns IS2325B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11164698P 1998-12-09 1998-12-09
PCT/US1999/029136 WO2000033847A1 (en) 1998-12-09 1999-12-08 Micronized eplerenone compositions

Publications (2)

Publication Number Publication Date
IS5953A IS5953A (is) 2001-05-25
IS2325B true IS2325B (is) 2007-12-15

Family

ID=22339668

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5953A IS2325B (is) 1998-12-09 2001-05-25 Örgerðar samsetningar epleróns

Country Status (30)

Country Link
US (7) US6410054B1 (is)
EP (1) EP1135139B1 (is)
JP (1) JP2002531508A (is)
KR (1) KR100671275B1 (is)
CN (1) CN1230179C (is)
AR (1) AR028982A1 (is)
AT (1) ATE249223T1 (is)
AU (1) AU763166B2 (is)
BR (1) BR9915964A (is)
CA (1) CA2326842A1 (is)
CZ (1) CZ20011942A3 (is)
DE (1) DE69911240T2 (is)
DK (1) DK1135139T3 (is)
EA (1) EA003266B1 (is)
ES (1) ES2207977T3 (is)
HK (1) HK1041641B (is)
HU (1) HU224428B1 (is)
ID (1) ID30115A (is)
IL (1) IL143301A0 (is)
IS (1) IS2325B (is)
MY (1) MY125651A (is)
NO (1) NO20012782L (is)
NZ (1) NZ511869A (is)
PL (1) PL198425B1 (is)
PT (1) PT1135139E (is)
TR (1) TR200101643T2 (is)
TW (1) TWI234459B (is)
UA (1) UA74141C2 (is)
WO (1) WO2000033847A1 (is)
ZA (1) ZA200104361B (is)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
EP1280533A2 (en) * 2000-05-11 2003-02-05 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
US20020123485A1 (en) * 2000-07-27 2002-09-05 Alexander John C. Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
CA2416152A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
CA2419256A1 (en) * 2000-08-28 2002-03-07 Kenton N. Fedde Use of an aldosterone receptor antagonist to improve cognitive function
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
DE60220522T2 (de) * 2001-07-19 2007-09-27 Pharmacia Corp. Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
KR20040071723A (ko) * 2001-12-13 2004-08-12 파마시아 코포레이션 에폭시-스테로이드 알도스테론 길항제를 사용하는 대상의알도스테론-매개 병원성 효과의 치료 또는 예방 방법
MXPA04007128A (es) * 2002-01-30 2005-03-31 Pharmacia Corp Politerapia con antagonista de aldosterona y agente antiinflamatorio no esteroideo para prevenir o tratar trastornos cardiovasculares.
KR20100090726A (ko) * 2002-02-26 2010-08-16 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
AU2003225871A1 (en) * 2002-03-20 2003-10-08 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
PL372055A1 (en) * 2002-04-26 2005-07-11 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
WO2004017906A2 (en) * 2002-08-23 2004-03-04 Pharmacia Corporation Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
DE60330888D1 (de) * 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
ATE411010T1 (de) * 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
JP2006524699A (ja) * 2003-04-25 2006-11-02 ノヴァカーディア，インク． 腎機能障害を持つ個体における利尿改善法
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
EP2529730A1 (en) * 2003-06-16 2012-12-05 ANDRX Pharmaceuticals LLC. Oral sustained-release composition
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
JP5026077B2 (ja) * 2003-09-12 2012-09-12 アムジエン・インコーポレーテツド カルシウム受容体−活性化合物の急速溶解処方
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
KR20070008689A (ko) * 2004-04-16 2007-01-17 노바카르디아, 인코포레이션 아데노신 ａ１ 수용체 길항제 및 알도스테론 억제제를포함하는 병용 요법
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
US7846466B2 (en) * 2004-06-10 2010-12-07 Northwestern University Biodegradable scaffolds and uses thereof
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20090176846A1 (en) * 2004-11-23 2009-07-09 Jei Man Ryu N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl-1, 3-thiazol-4-yl) phenoxy] pentoxy} benzamidine 2 methanesulfonic acid salt
WO2006097342A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process for making steroidal compounds
US20060252738A1 (en) * 2005-05-06 2006-11-09 Phero Tech Inc. Method for preparing and using water-based steroid pheromone compositions
WO2006125304A1 (en) * 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
US20070095705A1 (en) * 2005-10-31 2007-05-03 Legault Dennis X Array of packages
EP1977234B1 (en) * 2006-01-13 2015-11-04 Indiana University Research & Technology Corporation Type V collagen for use in a method of treatment of idiopathic pulmonary fibrosis
US20070184163A1 (en) * 2006-02-07 2007-08-09 International Flavors, & Fragrances Inc. Non-hygroscopic flavor particles
US20090175934A1 (en) * 2006-03-08 2009-07-09 Jubilant Organosys Ltd. Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
RU2446800C2 (ru) * 2006-05-31 2012-04-10 Вертекс Фармасьютикалз Инкорпорейтед Препаративные формы с контролируемым высвобождением
WO2007149366A1 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
US20100086586A1 (en) * 2006-12-21 2010-04-08 Brett Antony Mooney Pharmaceutical Composition
WO2008089549A1 (en) * 2007-01-22 2008-07-31 Genpharm Ulc Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
EP2124901B1 (en) 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20090232896A1 (en) * 2008-03-11 2009-09-17 Mallinckrodt Inc. Use of Magnesium Stearate Dihydrate for Lubrication of Solid Pharmaceutical Compositions
WO2010014952A2 (en) * 2008-07-31 2010-02-04 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
SI2470165T1 (en) * 2009-08-28 2018-08-31 Hercules Llc Composition of film for coating from solid powdery compounds
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
WO2011076749A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
WO2011076412A1 (de) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Orale darreichungsform umfassend entecavir
JP5669837B2 (ja) * 2010-06-16 2015-02-18 帝人ファーマ株式会社 放出制御型の有核錠剤
TR201007653A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
KR20120093461A (ko) * 2011-01-27 2012-08-23 양지화학 주식회사 정제형 감미료 조성물 및 그 제조방법
JP6284884B2 (ja) 2011-11-25 2018-02-28 ビルギチ，マフムト 吸入装置
US9682093B2 (en) 2012-03-30 2017-06-20 Charles R. Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
NZ702548A (en) 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
FR3001890B1 (fr) * 2013-02-08 2015-08-07 Greenpharma Sas Composition dermatologique pour repousse des poils ou des cheveux
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
US11007203B2 (en) * 2013-10-06 2021-05-18 Salim Shah Formulations comprising aldosterone receptor antagonists and treatments using same
US10716783B2 (en) 2013-12-12 2020-07-21 Cornell University Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom
FR3019045A1 (fr) * 2014-03-26 2015-10-02 Greenpharma Sas Composition dermatologique pour la repousse des poils ou des cheveux
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
WO2016063269A1 (en) 2014-10-20 2016-04-28 Prendergast Patrick T Use of antagonists to the nuclear steroid receptor alone or in combination as direct antiviral agents to inhibit alphavirus, togaviridae, arenaviridae, filoviridae, bunyaviridae, flaviviridae and rhabdoviridae
CA2978593A1 (en) 2015-01-12 2016-07-21 Nano Pharmaceutical Laboratories Llc Layered sustained-release microbeads and methods of making the same
BR122023020985A2 (pt) 2015-03-03 2023-12-26 Pharmacyclics Llc Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082751A (en) * 1976-02-13 1978-04-04 Bristol-Myers Company Therapeutic agents
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4753802A (en) 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4847093A (en) 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
GB8717168D0 (en) 1987-07-21 1987-08-26 Roussel Lab Ltd Controlled-release device
NZ238867A (en) 1990-07-12 1993-08-26 Alza Corp Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
WO1992013547A1 (en) 1991-02-07 1992-08-20 Alexander Mellon Eaton Drug delivery composition and method of using the same
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
GB9311191D0 (en) 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
AU5692398A (en) 1996-12-09 1998-07-03 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
KR100523409B1 (ko) 1996-12-11 2005-10-24 지.디. 썰 엘엘씨 9,11-에폭시 스테로이드의 제조방법 및 이 제조방법에유용한 중간체
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon

Also Published As

Publication number Publication date
KR20010101132A (ko) 2001-11-14
US6495165B1 (en) 2002-12-17
IL143301A0 (en) 2002-04-21
ATE249223T1 (de) 2003-09-15
TWI234459B (en) 2005-06-21
US20020136775A1 (en) 2002-09-26
DE69911240T2 (de) 2004-07-15
EP1135139B1 (en) 2003-09-10
US6410054B1 (en) 2002-06-25
CN1230179C (zh) 2005-12-07
CN1329494A (zh) 2002-01-02
US6534093B1 (en) 2003-03-18
US20030215518A1 (en) 2003-11-20
US6863902B2 (en) 2005-03-08
HUP0104718A2 (hu) 2003-01-01
CZ20011942A3 (cs) 2001-12-12
IS5953A (is) 2001-05-25
EA003266B1 (ru) 2003-02-27
MY125651A (en) 2006-08-30
HU224428B1 (hu) 2005-09-28
HK1041641A1 (en) 2002-07-19
DK1135139T3 (da) 2004-01-05
US6592902B2 (en) 2003-07-15
US20030072808A1 (en) 2003-04-17
CA2326842A1 (en) 2000-06-15
BR9915964A (pt) 2001-08-28
KR100671275B1 (ko) 2007-01-19
WO2000033847A1 (en) 2000-06-15
HK1041641B (zh) 2006-04-28
PT1135139E (pt) 2004-02-27
TR200101643T2 (tr) 2002-04-22
NO20012782D0 (no) 2001-06-06
UA74141C2 (uk) 2005-11-15
US6558707B1 (en) 2003-05-06
US7157101B2 (en) 2007-01-02
US20040192661A1 (en) 2004-09-30
JP2002531508A (ja) 2002-09-24
AU1936800A (en) 2000-06-26
ID30115A (id) 2001-11-08
AR028982A1 (es) 2003-06-04
EA200100519A1 (ru) 2002-02-28
AU763166B2 (en) 2003-07-17
ZA200104361B (en) 2002-05-28
NZ511869A (en) 2003-05-30
PL198425B1 (pl) 2008-06-30
ES2207977T3 (es) 2004-06-01
DE69911240D1 (de) 2003-10-16
EP1135139A1 (en) 2001-09-26
HUP0104718A3 (en) 2002-10-28
NO20012782L (no) 2001-07-03

Similar Documents

Publication Publication Date Title
IS2325B (is) Örgerðar samsetningar epleróns
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240D0 (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
PT1109558E (pt) Formulacoes de ranolazina de libertacao controlada
ID27092A (id) Pembuatan ftalat anhidrida
PT945132E (pt) Composicao de ibuprofeno
DE69805443T2 (de) Sachet-formulierungen
ID29021A (id) Komposisi galantamina pelepasan terkontrol
MA24473A1 (fr) Formulations
ID23299A (id) Formulasi-formulasi farmasi
EE200000693A (et) Uudsed makroosakeste formulatsioonid
CY2006006I1 (el) Πρωτεϊνικα σκευασματα
ATE227074T1 (de) Mikrokapsel-formulierungen
PT1014987E (pt) Composicoes orais de levosimendano
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
IS6398A (is) Lyfjablöndur
ATE232683T1 (de) Mikrokapsel-formulierungen
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
NO20005722D0 (no) Brusetilberedninger
EE9900594A (et) Uued astmavastased ravimkoostised
PT1232141E (pt) Eteres de o-desmetil-venlafaxina